Compare Jumia Technologies AG - ADR (JMIA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs 10X Genomics Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.27 (market cap $783.99M), while 10X Genomics Inc trades at $46.21 (market cap $5.48B). The key difference: 10X Genomics Inc is far larger — about 7× Jumia Technologies AG - ADR's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| JMIA | TXG | |
|---|---|---|
Market Cap | $783.99M | $5.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $45.80 |
52-Week Low | $4.45 | $11.34 |
Enterprise Value | $731.09M | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.
JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
